The use of a validated tool for risk assessment, combined with rapid follow-up, led to a lower risk of death or hospitalization for cardiovascular causes at 30 days among patients with acute heart failure. #AHA22 https://t.co/0cbvcHl3US
#ICYMI the recording of September's #CWMGR presented by Drs. Bruce Perkins and Susanna Mak on "The expanding multiverse of sodium-glucose linked transporter inhibition (SGLTi) in and beyond diabetes" is now available: https://t.co/AHdBXWWjaG @BBDC_UofT@SinaiHealth@MakLab_
Systematic review: sex-specific #reporting of #trial flow & outcomes in #HF RCTs 2000-2020 @JACCJournals
Reporting sex breakdown of patients screened, consented, lost to f/u could improve our understanding of sex imbalance in trials
https://t.co/VjlfVxx5Ou
Thoughtful editorial by #KojiTakeda and #SameerSingh about our recent vasodilator study @TheJHLT. Agree we need to translate into actions! Shared decision making and perhaps a study of prophylactic RV tMCS? RHF after LVAD – from prediction to action - https://t.co/hWFF4Q2jaj
And we’re off! The #TestYourLimits team has officially begun our 800km cycle of the #DempsterHighway from Dawson City, Yukon to Inuvik, NWT. Follow the adventure by checking out the @UHNFoundation Dempster Blog 2022: https://t.co/MdU1ecyCPD
Nice to see this new study in @EHJACVCEiC which adds further evidence to our recent study in @TheJHLT (https://t.co/86d91IvOb0) that vasodilator testing has a role in predicting RHF after LVAD implant. In this study, post-NTP PAPi was a good predictor.
https://t.co/0bY6swQzwm